​
​

Infinity Pharmaceuticals (INFI) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

INFI Stock Forecast

Infinity Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

INFI Analyst Ratings

Buy

According to 3 Wall Street analysts, Infinity Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for INFI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 16, 2022B. Riley SecuritiesNeutralDowngrade
May 23, 2022Piper SandlerOverweightOverweightHold
Jul 28, 2021Wells FargoOverweightUpgrade
Row per page
Go to

Infinity Pharmaceuticals's last stock rating was published by B. Riley Securities on Nov 16, 2022. The company Downgrade its INFI rating from "null" to "Neutral".

Infinity Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SQZSQZ Bio--90809.09%Buy
ADTXAditxt--46958.82%
INFIInfinity Pharmaceuticals--29900.00%Buy
CTMXCytomX Therapeutics--543.82%Buy
DRMADermata Therapeutics--426.32%Buy
CCCCC4 Therapeutics--217.65%Buy
TILInstil Bio--199.24%Hold
TRVITrevi Therapeutics--174.91%Buy
LYRALyra Therapeutics--163.16%Hold
NXTCNextCure--152.10%Buy
NUVBNuvation Bio--141.07%Buy
ERASErasca--140.74%Buy
ASMBAssembly Biosciences--136.04%Buy
KRONKronos Bio--81.11%Buy
EWTXEdgewise Therapeutics--39.75%Buy

INFI Forecast FAQ

Is Infinity Pharmaceuticals a good buy?

Yes, according to 3 Wall Street analysts, Infinity Pharmaceuticals (INFI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of INFI's total ratings.